ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 21 Jun 2023
Last Updated on 21 Jun 2023
A- A+
Guidance Recommendation

The Ministry of Health’s Medical Technology Advisory Committee has recommended subsidy for minimally invasive glaucoma surgery (MIGS) implants, as a standalone intervention or in conjunction with cataract surgery, for the treatment of patients with mild to moderate primary open-angle glaucoma (POAG) who are not adequately responsive to or are intolerant of anti-glaucoma medication.

Funding status

MIGS implants are recommended for inclusion in the Medical Technology Subsidy List (MTSL). Only listed models are recommended for subsidy when used in line with the abovementioned recommendations.


MIGS implants for treating patients with mild to moderate POAG